Search results
Results from the WOW.Com Content Network
During the American colonial era, tuberculosis was a major health concern in the Philippines. In 1910, a regional meeting was held in Manila and it was reported the mortality of the disease is estimated to be 40,000. [4] The health situation led to the establishment of the Philippine Islands Anti-Tuberculosis Society on July 29, 1910.
Facade of the PMA Philippine Medical Association Secretariat (PMA Bldg., North Avenue, Quezon City 1105). National historical marker installed in 1992. Philippine Medical Association is the primary medical association of the Philippines, covering medical practitioners and component medical groups from the entire country.
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB. The medical standard for active TB is a short course treatment involving a combination of isoniazid , rifampicin (also known as Rifampin), pyrazinamide , and ethambutol for the first two months.
Directly observed treatment, short-course (DOTS, also known as TB-DOTS) is the name given to the tuberculosis (TB) control strategy recommended by the World Health Organization. [1] According to WHO, "The most cost-effective way to stop the spread of TB in communities with a high incidence is by curing it.
The Global Fund’s investments have reduced deaths from HIV, tuberculosis, and malaria by 61% since 2002, saving 65 million lives. [25] Recent efforts include lowering the cost of key treatments for drug-resistant TB by 55% and first-line HIV medications by 25%, while introducing a more effective insecticide-treated mosquito net. [26]
The Lung Center of the Philippines (LCP) is a government tertiary hospital specializing in the prevention and cure of lung and other chest diseases, located on Central, Quezon City, Philippines. The center receives budgetary support for its operations from the national government. [ 1 ]
A 2008 study in the Tomsk oblast of Russia, reported that 14 out of 29 (48.3%) patients with XDR-TB successfully completed treatment. [16] In 2018, the WHO reported that the treatment success rate for XDR-TB was 34% for the 2015 cohort, compared to 55% for MDR/RR-TB (2015 cohort), 77% for HIV-associated TB (2016 cohort), and 82% for TB (2016 ...
Lengthier treatment, often in hospitals, substantially increases health care costs as well as the economic burden on families and societies. The cost of treating a single case of multidrug-resistant TB (MDR-TB) or extensively drug-resistant TB (XDR-TB) can be thousands of times more expensive than treating drug-sensitive TB. [7]